Avapritinib’s clinical development initially targeted patients with unresectable or metastatic GIST harboring PDGFRA exon 18 mutations—particularly D842V—a population historically refractory to imatinib, sunitinib, and regorafenib [47,156,157]. The gene discussed is PDGFRA; the disease is gastrointestinal stromal tumor.